RemeGen Co Ltd - Class A

SHSE:688331 (China)   Class A
Â¥ 39.53 (+4.91%) Dec 3
At Loss
P/B:
3.88
Market Cap:
Â¥ 17.37B ($ 2.38B)
Enterprise V:
Â¥ 18.08B ($ 2.48B)
Volume:
493.27M
Avg Vol (2M):
5.13M
Trade In:
Volume:
493.27M
At Loss

Business Description

Description
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
Name Current Vs Industry Vs History
Cash-To-Debt 0.37
Equity-to-Asset 0.46
Debt-to-Equity 0.9
Debt-to-EBITDA -1.88
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.99
Distress
Grey
Safe
Beneish M-Score -2.21
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 77.68
9-Day RSI 69.04
14-Day RSI 64.85
6-1 Month Momentum % -16.91
12-1 Month Momentum % -46.5

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.51
Quick Ratio 1.06
Cash Ratio 0.53
Days Inventory 836.09
Days Sales Outstanding 66.21
Days Payable 204.3

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -3.6
Shareholder Yield % -9.11

Financials (Next Earnings Date:2025-04-25 Est.)

SHSE:688331's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

RemeGen Co Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ¥) 1,396.713
EPS (TTM) (Â¥) -2.95
Beta 0
Volatility % 80.83
14-Day RSI 64.85
14-Day ATR (Â¥) 2.471271
20-Day SMA (Â¥) 35.3395
12-1 Month Momentum % -46.5
52-Week Range (Â¥) 22.37 - 71.8
Shares Outstanding (Mil) 544.26

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

RemeGen Co Ltd Filings

Filing Date Document Date Form
No Filing Data

RemeGen Co Ltd Stock Events

Financials Calendars
Event Date Price(Â¥)
No Event Data

RemeGen Co Ltd Frequently Asked Questions

What is RemeGen Co Ltd(SHSE:688331)'s stock price today?
The current price of SHSE:688331 is ¥39.53. The 52 week high of SHSE:688331 is ¥71.80 and 52 week low is ¥22.37.
When is next earnings date of RemeGen Co Ltd(SHSE:688331)?
The next earnings date of RemeGen Co Ltd(SHSE:688331) is 2025-04-25 Est..
Does RemeGen Co Ltd(SHSE:688331) pay dividends? If so, how much?
RemeGen Co Ltd(SHSE:688331) does not pay dividend.

Press Release

Subject Date
No Press Release